Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData
16th April 2024 Uncategorised 0 Arrowhead’s plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData
apark
Tue, 04/16/2024 – 12:43
More: Arrowhead's plozasiran could reach 0M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData
Source: fierce
